MedTrace Logo

Study of Efficacy and Safety of AMG 334 in Adult Episodic Migraine Patients

NCT03333109 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 900

Last updated 2021-10-11

Study results available
· View outcomes & findings →

Summary

This study is to evaluate the efficacy and safety of AMG334 in adult patients with episodic migraine

Conditions

  • Episodic Migraine

Interventions

BIOLOGICAL

Erenumab

70 mg/mL pre-filled syringe administered subcutaneously

OTHER

Placebo

Matching placebo in pre-filled syringe administered subcutaneously

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-08
Primary Completion
2020-01-13
Completion
2020-01-13
FDA Drug
Yes

Countries

  • Argentina
  • India
  • Lebanon
  • Malaysia
  • Mexico
  • Philippines
  • Singapore
  • South Korea
  • Taiwan
  • Thailand
  • Vietnam

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03333109 on ClinicalTrials.gov